Claims for Patent: 10,220,048

Summary for Patent: 10,220,048

Title:	Compositions and methods for treating ocular diseases
Abstract:	Disclosed herein are compositions and methods for treating ocular diseases, inter alia, diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like. These diseases or conditions are characterized by changes in the ocular vasculature whether progressive or non-progressive, whether a result of an acute disease or condition, or a chronic disease or condition.
Inventor(s):	Peters; Kevin (Cincinnati, OH), Shalwitz; Robert (Bexley, OH)
Assignee:	AERPIO THERAPEUTICS, INC. (Cincinnati, OH)
Application Number:	15/355,910
Patent Claims:	1. A method for treating diabetic macular edema, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the formula: ##STR00353## or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of at least one anti-VEGF agent, wherein the anti-VEGF agent is ranibizumab, bevacizumab, or aflibercept. 2. The method according to claim 1, the method further comprising treating a retinopathy in the subject. 3. The method according to claim 1, wherein the therapeutically effective amount of the compound or pharmaceutically-acceptable salt thereof is from about 0.5 mg to about 30 mg per treatment. 4. The method according to claim 1, wherein the anti-VEGF agent is ranibizumab. 5. The method according to claim 4, wherein the therapeutically effective amount of ranibizumab is about 0.05 mg to about 1.5 mg. 6. The method according to claim 1, wherein the anti-VEGF agent is bevacizumab. 7. The method according to claim 6, wherein the therapeutically effective amount of bevacizumab is about 0.1 mg to about 5 mg. 8. The method according to claim 1, wherein the anti-VEGF agent is aflibercept. 9. The method according to claim 8, wherein the therapeutically effective amount of aflibercept is about 0.05 mg to about 5 mg. 10. The method according to claim 1, wherein the administration reduces central foveal thickness in an eye of the subject. 11. The method according to claim 1, wherein the administration improves visual acuity in an eye of the subject. 12. The method according to claim 1, wherein the anti-VEGF agent is ranibizumab, and wherein the therapeutically effective amount of ranibizumab is about 0.3 mg. 13. The method according to claim 1, wherein the therapeutically effective amount of the compound or the pharmaceutically acceptable salt thereof is about 15 mg per treatment.

Details for Patent 10,220,048

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2033-03-15
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2033-03-15
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2033-03-15